To: MAPMG and Network Physicians, Nurse Practitioners, Physician Assistants, and Pharmacy Department

Date: February 23, 2017

Subject: Notification of Part D Negative Tier Change effective April 4, 2017
Evzio SOAJ 0.4 MG/0.4 ML (Naloxone HCL)

From: KPMAS Pharmacy Department, Pharmacy Benefits
Carol Forster, MD
Physician Director, Pharmacy and Therapeutics / Medication Safety, MAPMG

Situation:
Effective April 4, 2017, EVZIO 0.4MG/0.4ML (naloxone) will be moved to the specialty tier for Medicare Part D members. This is a non-preferred form of naloxone. There is no change to the preferred forms; nasal naloxone 4mg spray (Tier 3) and naloxone injection (tier 2).

Background:
During the year, with Medicare approval, Kaiser Permanente may make changes to our Drug List. New drugs may be added, removed, and restrictions to coverage may be added or removed. Changes from one cost-sharing tier to another are also allowed. As part of our ongoing review of Part D prescription claims submitted to CMS, it was determined that EVZIO met the criteria for coverage under the Specialty Tier. This tier change has been approved by CMS for new member starts.

At this time, only one member will be impacted by this change. As the affected member was prescribed this drug prior to April 4, 2017, they will continue to receive this product if medically necessary at the Tier 4 cost share. Our preferred naloxone product for emergency treatment of opioid overdose is still nasal naloxone (NARCAN 4 mg ACTUATION NASL SPRAY) and is covered for Medicare members on Tier 3. Naloxone injection is also still covered on Tier 2.

Assessment:
A Medicare tier change for EVZIO will go into effect April 4, 2017 when it is moved to the specialty tier. The status of preferred nasal naloxone and naloxone injectable products will remain unchanged.

<table>
<thead>
<tr>
<th>Reason for change</th>
<th>Drug Name/ Description</th>
<th>Date and Type of Change</th>
<th>Alternate Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost Sharing Increase</td>
<td>EVZIO SOAJ 0.4 MG/0.4 ML</td>
<td>April 4, 2017 Tier Change from Tier 4 to Tier 5</td>
<td>Other forms of Naloxone such as:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tier 2: INJECTION: NALOXONE HCL SOLN 0.4 MG/ML</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tier 3: NASAL LIQUID: NARCAN LIQD 4 MG/0.1ML</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NALOXONE HCL 4 MG/0.1 ML NASAL SPRAY</td>
</tr>
</tbody>
</table>

Request:
1. Please be aware of this Tier cost share change of EVZIO SOAJ 0.4 MG/0.4ML (Naloxone HCL) effective April 4, 2017
2. Please direct members with questions regarding this change to Membership Services at 1-888-777-5536 or 1-866-513-0008 TTY 8AM to 8PM, 7 days a week.

Thank you for your assistance with this important pharmacy benefit update!